JP2024540410A5 - - Google Patents
Info
- Publication number
- JP2024540410A5 JP2024540410A5 JP2024527135A JP2024527135A JP2024540410A5 JP 2024540410 A5 JP2024540410 A5 JP 2024540410A5 JP 2024527135 A JP2024527135 A JP 2024527135A JP 2024527135 A JP2024527135 A JP 2024527135A JP 2024540410 A5 JP2024540410 A5 JP 2024540410A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- group
- compound
- alkyl
- heterocyclic group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163276478P | 2021-11-05 | 2021-11-05 | |
| US63/276,478 | 2021-11-05 | ||
| US202263356906P | 2022-06-29 | 2022-06-29 | |
| US63/356,906 | 2022-06-29 | ||
| US202263403565P | 2022-09-02 | 2022-09-02 | |
| US63/403,565 | 2022-09-02 | ||
| PCT/US2022/079324 WO2023081840A1 (en) | 2021-11-05 | 2022-11-04 | Kras g12c inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540410A JP2024540410A (ja) | 2024-10-31 |
| JP2024540410A5 true JP2024540410A5 (https=) | 2025-11-12 |
Family
ID=84537713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527135A Pending JP2024540410A (ja) | 2021-11-05 | 2022-11-04 | Ｋｒａｓ ｇ１２ｃ阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20250340548A1 (https=) |
| EP (1) | EP4426695A1 (https=) |
| JP (1) | JP2024540410A (https=) |
| KR (1) | KR20240114793A (https=) |
| AU (1) | AU2022380839A1 (https=) |
| CA (1) | CA3236238A1 (https=) |
| IL (1) | IL312381A (https=) |
| MX (1) | MX2024005228A (https=) |
| TW (1) | TW202334138A (https=) |
| WO (1) | WO2023081840A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312381A (en) | 2021-11-05 | 2024-06-01 | Frontier Medicines Corp | KRAS G12C inhibitors |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| JP2025510656A (ja) * | 2022-03-24 | 2025-04-15 | ベイジーン スウィッツァーランド ゲーエムベーハー | 複素環式化合物、その組成物、及びそれらを用いた治療方法 |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| CN119630676A (zh) * | 2022-06-10 | 2025-03-14 | 百时美施贵宝公司 | 作为kras抑制剂的吡啶并[4,3-d]嘧啶衍生物 |
| CN119317629A (zh) * | 2022-06-10 | 2025-01-14 | 百时美施贵宝公司 | 作为kras抑制剂的四氢吡啶并3,4-d嘧啶衍生物 |
| WO2023246777A1 (en) * | 2022-06-20 | 2023-12-28 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| EP4547666A1 (en) * | 2022-06-29 | 2025-05-07 | Frontier Medicines Corporation | Methods for treatment of cancer |
| KR20260041941A (ko) | 2023-03-15 | 2026-03-27 | 콴타 테라퓨틱스, 인크. | Kras 조절 인자 및 이의 용도 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| EP4705302A1 (en) * | 2023-05-04 | 2026-03-11 | Frontier Medicines Corporation | Pyrido[4,3-d]pyrimidine derivatives as mutant kras g12c inhibitors for the treatment of cancer |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025085580A1 (en) * | 2023-10-17 | 2025-04-24 | Windermere Therapeutics, Inc. | Kras(g12d) inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025179058A1 (en) | 2024-02-21 | 2025-08-28 | Frontier Medicines Corporation | Pyridopyrimidine derivative as kras g12c inhibitor for the treatment of brain metastasis |
| WO2025188668A1 (en) | 2024-03-04 | 2025-09-12 | Frontier Medicines Corporation | Combination of a kras g12c inhibitor with an immune checkpoint inhibitor for the treatment of cancer |
| WO2025194340A1 (en) | 2024-03-19 | 2025-09-25 | Frontier Medicines Corporation | Polymorphic forms of kras inhibitors and uses thereof |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026035947A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102444509B1 (ko) * | 2016-05-18 | 2022-09-19 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
| EP3403569A1 (en) * | 2017-05-17 | 2018-11-21 | Koninklijke Philips N.V. | System for milk ejection reflex determination |
| LT3710439T (lt) | 2017-11-15 | 2023-05-10 | Mirati Therapeutics, Inc. | Kras g12c inhibitoriai |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| ES3017461T3 (en) | 2018-09-10 | 2025-05-13 | Mirati Therapeutics Inc | Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer |
| EP3849535A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3849537B1 (en) | 2018-09-10 | 2024-10-23 | Mirati Therapeutics, Inc. | Combination therapies |
| MX2021002804A (es) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| CN112694475B (zh) | 2019-10-23 | 2025-09-23 | 苏州泽璟生物制药股份有限公司 | 环烷基类和杂环烷基类抑制剂及其制备方法和应用 |
| CN113045565A (zh) * | 2019-12-27 | 2021-06-29 | 微境生物医药科技(上海)有限公司 | 新型K-Ras G12C抑制剂 |
| CN115135650A (zh) | 2020-02-20 | 2022-09-30 | 贝达医药公司 | 作为kras抑制剂的吡啶并嘧啶衍生物 |
| WO2021244603A1 (en) | 2020-06-04 | 2021-12-09 | Shanghai Antengene Corporation Limited | Inhibitors of kras g12c protein and uses thereof |
| EP4204412A4 (en) | 2020-08-26 | 2024-10-09 | InventisBio Co., Ltd. | HETEROARYL COMPOUNDS, PRODUCTION PROCESSES AND USES THEREOF |
| JP2023553492A (ja) | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| WO2022187527A1 (en) | 2021-03-05 | 2022-09-09 | Nikang Therapeutics, Inc | Quinazoline nitrile derivatives as kras inhibitors |
| BR112023024906A2 (pt) | 2021-05-28 | 2024-02-15 | Redx Pharma Plc | Compostos |
| WO2022256459A1 (en) | 2021-06-01 | 2022-12-08 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| AR126166A1 (es) | 2021-06-18 | 2023-09-27 | Antengene Discovery Ltd | Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos |
| WO2022271823A1 (en) | 2021-06-23 | 2022-12-29 | Newave Pharmaceutical Inc. | Mutant kras modulators and uses thereof |
| IL310291A (en) | 2021-07-23 | 2024-03-01 | Theras Inc | Compositions and methods for inhibition of ras |
| IL312381A (en) | 2021-11-05 | 2024-06-01 | Frontier Medicines Corp | KRAS G12C inhibitors |
| AR128212A1 (es) | 2022-01-06 | 2024-04-10 | Theras Inc | Composiciones y métodos para la inhibición de ras |
| WO2023137223A1 (en) | 2022-01-17 | 2023-07-20 | Newave Pharmaceutical Inc. | Pan-kras inhibitors and uses thereof |
| WO2023225252A1 (en) | 2022-05-20 | 2023-11-23 | Theras, Inc. | Compositions and methods for inhibition of ras |
| CN119630676A (zh) | 2022-06-10 | 2025-03-14 | 百时美施贵宝公司 | 作为kras抑制剂的吡啶并[4,3-d]嘧啶衍生物 |
| EP4547666A1 (en) | 2022-06-29 | 2025-05-07 | Frontier Medicines Corporation | Methods for treatment of cancer |
| JP2025526744A (ja) | 2022-08-11 | 2025-08-15 | ブリストル－マイヤーズ スクイブ カンパニー | Ｋｒａｓ阻害剤 |
| WO2024138206A1 (en) | 2022-12-23 | 2024-06-27 | Frontier Medicines Corporation | Fluoropyridopyrimidine and fluoroquinazoline derivaties and methods of use thereof |
| EP4655298A1 (en) | 2023-01-24 | 2025-12-03 | Theras Inc. | Compositions and methods for inhibition of ras |
-
2022
- 2022-11-04 IL IL312381A patent/IL312381A/en unknown
- 2022-11-04 KR KR1020247018884A patent/KR20240114793A/ko active Pending
- 2022-11-04 AU AU2022380839A patent/AU2022380839A1/en active Pending
- 2022-11-04 EP EP22826536.9A patent/EP4426695A1/en active Pending
- 2022-11-04 WO PCT/US2022/079324 patent/WO2023081840A1/en not_active Ceased
- 2022-11-04 MX MX2024005228A patent/MX2024005228A/es unknown
- 2022-11-04 JP JP2024527135A patent/JP2024540410A/ja active Pending
- 2022-11-04 US US18/707,499 patent/US20250340548A1/en active Pending
- 2022-11-04 CA CA3236238A patent/CA3236238A1/en active Pending
- 2022-11-04 TW TW111142228A patent/TW202334138A/zh unknown
-
2024
- 2024-07-24 US US18/783,394 patent/US12291539B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024540410A5 (https=) | ||
| ES2534326T3 (es) | Compuestos tricíclicos heterocíclicos como inhibidores de la fosfoinositida 3-cinasa | |
| KR102667914B1 (ko) | Rsv 저해제로서의 벤조다이아제핀 유도체 | |
| CN107108588B (zh) | 可用于治疗癌症的稠合双环(杂)芳香族化合物 | |
| AU2022288151A1 (en) | Quinazoline derivatives useful as ras inhibitiors | |
| KR20250057027A (ko) | Kras g12d 억제제 | |
| JP2021532061A (ja) | 四環式ヘテロアリール化合物 | |
| BR112020019385A2 (pt) | Inibidores de shp2 fosfatase e métodos de uso dos mesmos | |
| JP2025523624A (ja) | がんの治療のための方法 | |
| CN112334451A (zh) | 作为激酶抑制剂的杂环化合物 | |
| JP2008528467A5 (https=) | ||
| BR112020022224A2 (pt) | inibidores heterocíclicos substituídos de ptpn11 | |
| KR20210100155A (ko) | Ret 억제제, 이의 약학 조성물 및 용도 | |
| CA3037064A1 (en) | Spirocyclic compounds | |
| JP7137733B2 (ja) | ｔｏｌｌ様受容体アゴニストとしてのイミダゾ［４，５－Ｃ］ピリジン誘導体 | |
| WO2014188173A1 (en) | Pyrazolopyrimidine derivatives useful as inhibitors of bruton's tyrosine kinase | |
| NZ586990A (en) | Conformationally restricted biphenyl derivatives for use as hepatitis c virus inhibitors | |
| WO2016046530A1 (en) | Novel compounds | |
| BR112020015583A2 (pt) | composto, composição farmacêutica, e, métodos para inibir a atividade de prc2 em uma célula e para tratar câncer | |
| JP6737533B2 (ja) | スピロ環式化合物 | |
| CN115298183A (zh) | 作为酪蛋白激酶抑制剂的化合物 | |
| JP7713619B2 (ja) | 大員環分子およびそれらの使用 | |
| CA3239857A1 (en) | Carbonyl substituted diazaspiro compounds and its use | |
| IL324276A (en) | Egfr inhibitors for treating disease | |
| WO2025043225A2 (en) | Degraders of cyclin-dependent kinase 2 |